Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca teams with Heptares

AstraZeneca has teamed up with UK-based drug discovery company Heptares in a four-year collaboration to develop new therapies that target proteins linked to nervous system and cardiovascular disorders

AstraZeneca (AZ) has teamed up with UK-based drug discovery company Heptares in a four-year collaboration to develop new therapies that target proteins linked to nervous system and cardiovascular disorders.

The deal includes a £3.8m payment to Heptares, which will also be eligible for royalties from any successful products, while AZ will gain the worldwide rights.

The collaboration will make use of Heptares' G protein-coupled receptors (GPCR) discovery expertise and proprietary technologies - including its StaR technology, which engineers stabilised receptors allowing GPCRs to be investigated.

GPCRs are one of the largest family of proteins, yet have an inherent instability when removed from cell membranes, according to a statement from AZ. 

Research conducted under the collaboration will focus on a number of specific GPCR targets linked to central nervous system/pain, cardiovascular/metabolic and inflammatory disorders from projects in AZ's small and large molecule portfolio, including projects from AZ's biologics unit, MedImmune.

Martin Mackay, president of research and development, AZ, said: "Our work will focus on a range of different diseases across our small and large molecule portfolio with the goal of discovering innovative treatments for patients in areas of medical need."

31st May 2011

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield Commercial & Medical Services

Ashfield Commercial & Medical Services, part of UDG Healthcare plc, is a leading international provider of services to healthcare manufactures...

Latest intelligence

Easier access to medicines in the UK?
Cutting through the NICE value-based assessment consultation to find out what’s at stake...
Exploring MINT: Part 3 - Nigeria
In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria....
BL_Where_Now_20140721_CoverImage.jpg
3 Steps to Navigating Multichannel in Healthcare
You know about multichannel, but... where now? Download the 3 Steps to Navigating Multichannel in Healthcare ebook to learn what you should do next when planning your multichannel campaign....